Guggenheim analyst Vamil Divan has maintained a Buy rating on Johnson & Johnson and increased the price target to $270 from the previous $266. The adjustment reflects an updated valuation outlook for the healthcare conglomerate.

Rating and Price Target Details

The revised price target of $270 represents an increase from the prior level of $266. Johnson & Johnson continues to carry a Buy recommendation from the firm.

Johnson & Johnson today announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe, expanding physician access to a dual-energy catheter ablation solution. The platform is designed to provide personalized care across workflows, anatomies, and procedural strategies by combining pulsed field and radiofrequency energy delivery in a unified system.

The DE STSF Platform integrates the Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, an irrigated contact-force sensing catheter, with the TRUPULSE Generator. This configuration enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single catheter during the same procedure. The system leverages CARTO integration, ultra high-density mapping solutions, and intracardiac ultrasound imaging to provide advanced electro-anatomical mapping, catheter visualization, contact-force feedback, and PF/RF Index guidance.

Built upon the THERMOCOOL SMARTTOUCH SF platform, which has treated more than a million patients worldwide, the new system maintains a familiar point-by-point workflow. It allows physicians to switch between RF and PFA seamlessly, offering greater versatility to adjust treatment to different patient anatomies and clinical needs. This flexibility is intended to support procedural control and reproducible lesion creation.

"DE STSF is a welcome addition to the EP lab because it allows physicians to incorporate new technology based on the gold RF standard smarttouch SF platform while maintaining familiar workflows with greater versatility by seamlessly switching between RF and PFA," said Nicolas Derval, M.D., of Bordeaux, France. "This flexibility also provides greater ability to adjust treatment to different patient anatomies, clinical needs and procedural goals while increasing safety in ablating the posterior wall for example."

Clinical data supporting the platform include 12-month findings from the SmartfIRE first-in-human study. The study demonstrated 86.9% effectiveness among patients treated with high adherence to the recommended workflow and PF/RF Index guidance. Additionally, the study showed clinically meaningful improvements in quality of life and reductions in cardiovascular-related hospitalizations and antiarrhythmic drug use.

"No two atrial fibrillation patients are the same, which is why personalized treatment and procedural versatility matter," said Ricardo Martin, President EMEA, Electrophysiology, MedTech, Johnson & Johnson. "The launch of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform reflects our continued commitment to providing physicians with a broad range of treatment options."

Key Clinical Data